Phio Pharmaceuticals (NASDAQ:PHIO) is a biotechnology firm focused on developing innovative cancer treatments. Its operations revolve around pioneering a new class of therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA) technology, aimed at empowering the immune system to fight tumors more effectively. The company's projects primarily involve preclinical and clinical research to design therapies that silence tumor-induced suppression of the immune system, thus enhancing the effectiveness of cancer treatments. Phio Pharmaceuticals strives to break new ground in cancer therapy, with the objective of bringing novel, more effective treatments to patients in need, demonstrating its commitment to advancing the fight against cancer through cutting-edge research and development.